Newleos Therapeutics (Series A)
Funding Details
- Awarder
- Inbox
- Date Award
- May 18, 2025
- Vertical
- Neuroscience
- Funding URL
- View Funding Page
- Funding Amount:
- $93,500,000
Company Info
- Founders
- Longwood Fund and seasoned leaders in CNS drug development
- Company Description
- Newleos Therapeutics is a clinical stage neuroscience company focused on developing oral small molecules targeting novel mechanisms for various CNS indications including generalized anxiety, social anxiety, substance use disorders, and cognitive impairment.
- Market
- CNS drug development
- Location
- Boston, MA, USA
- Coinvestors
- Goldman Sachs Alternatives, Novo Holdings A/S, Longwood Fund, DCVC Bio, Arkin Bio Capital